Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;21(10):1352-1354.
doi: 10.1016/S1473-3099(21)00568-5. Epub 2021 Aug 26.

CoronaVac induces lower neutralising activity against variants of concern than natural infection

Vimvara Vacharathit  1 , Pakorn Aiewsakun  2 , Suwimon Manopwisedjaroen  1 , Chanya Srisaowakarn  1 , Thanida Laopanupong  1 , Natali Ludowyke  1 , Angsana Phuphuakrat  3 , Chavachol Setthaudom  4 , Supanuch Ekronarongchai  1 , Sirawat Srichatrapimuk  5 , Pattama Wongsirisin  6 , Suleeporn Sangrajrang  6 , Thanarath Imsuwansri  6 , Suppachok Kirdlarp  5 , Sureeporn Nualkaew  6 , Insee Sensorn  7 , Waritta Sawaengdee  8 , Nuanjun Wichukchinda  8 , Somnuek Sungkanuparph  5 , Wasun Chantratita  7 , Mongkol Kunakorn  4 , Jinda Rojanamatin  6 , Suradej Hongeng  9 , Arunee Thitithanyanont  10
Affiliations

CoronaVac induces lower neutralising activity against variants of concern than natural infection

Vimvara Vacharathit et al. Lancet Infect Dis. 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. This work was supported by the National Research Council of Thailand, the Mahidol University for Integrated and Multidisciplinary Research Cluster grant (MRC-IM 02/2564), the Program Management Unit C, and the Ramathibodi Foundation.

References

    1. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192. - PMC - PubMed
    1. Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021 doi: 10.1056/nejmoa2107715. published online July 7. - DOI - PMC - PubMed
    1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211. - PubMed
    1. Wang G-L, Wang Z-Y, Duan L-J, et al. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N Engl J Med. 2021;384:2354–2356. - PMC - PubMed
    1. Fisman DN, Tuite AR. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada. medRxiv. 2021 doi: 10.1101/2021.07.05.21260050. published online July 12. (preprint). - DOI - PMC - PubMed

Publication types